Acipimox

Acipimox

Clinical data
ATC code	C10AD06 (WHO)
Identifiers
IUPAC name 5-methylpyrazine-2-carboxylic acid 4-oxide
CAS Number	51037-30-0
PubChem CID	5310993
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C6H6N2O3
Molar mass	154.124 g/mol

WikiDoc Resources for Acipimox
Articles
Most recent articles on Acipimox Most cited articles on Acipimox Review articles on Acipimox Articles on Acipimox in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Acipimox Images of Acipimox Photos of Acipimox Podcasts & MP3s on Acipimox Videos on Acipimox
Evidence Based Medicine
Cochrane Collaboration on Acipimox Bandolier on Acipimox TRIP on Acipimox
Clinical Trials
Ongoing Trials on Acipimox at Clinical Trials.gov Trial results on Acipimox Clinical Trials on Acipimox at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Acipimox NICE Guidance on Acipimox NHS PRODIGY Guidance FDA on Acipimox CDC on Acipimox
Books
Books on Acipimox
News
Acipimox in the news Be alerted to news on Acipimox News trends on Acipimox
Commentary
Blogs on Acipimox
Definitions
Definitions of Acipimox
Patient Resources / Community
Patient resources on Acipimox Discussion groups on Acipimox Patient Handouts on Acipimox Directions to Hospitals Treating Acipimox Risk calculators and risk factors for Acipimox
Healthcare Provider Resources
Symptoms of Acipimox Causes & Risk Factors for Acipimox Diagnostic studies for Acipimox Treatment of Acipimox
Continuing Medical Education (CME)
CME Programs on Acipimox
International
Acipimox en Espanol Acipimox en Francais
Business
Acipimox in the Marketplace Patents on Acipimox
Experimental / Informatics
List of terms related to Acipimox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.